​The Division of Rheumatology strives to understand more about lupus through research. Please see the list below, which summarizes the st​udies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB​#/PI | Brief Description​ | Basic Eligibility​ Criteria | °ä´Ç²Ô³Ù²¹³¦³Ù​ |
AstraZeneca (Lavendar) Kristen Demoruelle, MD, PhD | Evaluate the Efficacy and Safety of Anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus who are refractory adn/or intolerant to antimalarial therapy. Each study stage will have a randomized, double-blind, placebo-controlled design, followed by an open label treatment period. | 1. Adult women or men (ages 18-70) and a body weight of >=40.0 kg. 2. Confirmed diagnosis of chronic CLE (including discoid CLE adn other subtypes) and/or subacute CLE with or without systemic manifestation. 3. Either a BILAG A in one organ or a BILAG B in two organs 4. Must have current autoantibody positivity (ANA or dsDNA or anti-Smith) and low complement (C3 OR C4 OR CH50) at screening | Chong Pedrick 303-724-7518
Najeeb Arishi 303-724-7512
|
TOPAZ
IRB#
22-0670 | A multicenter, randomized, placebo-controlled, phase 3 study to evaluate the efficacy and safety of BIIB059 in adult participants with active SLE receiving background non-biologic standard of care treatment. | Participants must be at least 18 years old and diagnosed with SLE at least 24 weeks prior, meeting 2019 EULAR/ACR classification criteria for SLE. Disease activity will be determined by modified SLEDAI-2K and BILAG scores at screening. -Must have a modified clinical SLEDAI 2K score of at least 4 (excluding anti-dsDNA, low complement, alopecia, fever, headache and organic brain syndrome)
And -Must have a BILAG2004 level A disease in ≥ 1 organ system or BILAG2004 level B disease in ≥ 2 organ systems | Chong Pedrick 303-724-7518
Najeeb Arishi 303-724-7512 |
COSMIC IRB# 23-1287 Christopher Striebich, MD, PhD | Proof of concept study to evaluate the efficacy, safety, and tolerability of GS-5718 in participants with Cutaneous Lupus Erythematosus (CLE) To review the clinical trials.gov info click | -Active cutaneous lupus (either SLE or CLE) affecting more than one area -Willingness to undergo skin punch biopsy at 2 timepoints | Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |
Novartis SIRIUS IRB #23-1961 Christopher Striebich, MD, PhD | The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous injection on top of standard-of-care treatment in participants with active systemic lupus erythematosus (SLE) To review the clinical trials.gov info click | Eligibility:
| Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |
IDORSIA IRB #22-1370 Christopher Striebich, MD, PhD | The goal of this clinical trial is to see how well cenerimod is in reducing symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. To review the clinical trials.gov info click | Eligibility
| Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |
CAR-T study in SLE, IIM and SSc 24-0289 Melissa Griffith, MD | A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, idiopathic Inflammatory Myopathy or Systemic Sclerosis |
| Chong Pedrick 303-724-7518
Najeeb Arishi 303-724-7512
Mario Farag 303-724-6438 Mario.Farag@cuanschutz.edu |
Immunovant Elena Weinstein, MD | To evaluate the efficacy of IMVT-1402 compared to placebo in participants with CLE as assessed by changes in cutaneous lupus erythematosus disease area and severity index activity (CLASI-A) score. | Eligibility
| Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |
SELECT-SLE (Abbvie) Christopher Striebich, MD/PhD | Study to evaluate the safety and efficacy of JAK inhibitor Upadacitinib (Rinvoq) in individuals with moderat to severe active SLE. |
| Chong Pedrick 303-724-7518 Najeeb Arishi 303-724-7512 |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.